Literature DB >> 12479942

Nonalcoholic steatohepatitis: risk factors for liver fibrosis.

Masahiko Shimada1, Etsuko Hashimoto, Hiroyuki Kaneda, Sanshirou Noguchi, Naoaki Hayashi.   

Abstract

The purpose of this study was to clarify the clinicopathological features of nonalcoholic steatohepatitis (NASH) and identify risk factors for severe hepatic fibrosis.
MATERIALS AND METHODS: Eighty-one patients with biopsy-proven NASH were studied. In all patients, the diagnosis of NASH was established on the basis of following criteria: (1) the presence of steatosis, lobular inflammation, and ballooning degeneration on liver biopsy, (2) intake of less than 20 g of ethanol per week, and (3) appropriate exclusion of other liver diseases.
RESULTS: The median age was 54 years (range: 21-82 years) and 41 patients were women (51%). Obesity was present in 58 patients (72%), while 25 patients (31%) had diabetes mellitus and 33 patients (41%) had hyperlipidemia. Histologically, 58 patients (72%) had trivial to moderate fibrosis, 6 patients (7%) had bridging fibrosis, and 17 patients (21%) had established cirrhosis. Multiple logistic regression analysis assessed clinical, laboratory and histological factors showed that the risk factors for fibrosis were a low platelet count (P=0.0016), a high AST/ALT ratio (P=0.0229), and the presence of Mallory bodies (P=0.0209). To exclude factors that were a consequence of liver cirrhosis, variables included in the multiple logistic analysis were age, gender, diabetes, obesity, and hyperlipidemia. This showed that older age (P=0.0037) and the absence of hyperlipidemia (P=0.0150) were risk factors for fibrosis.
CONCLUSIONS: We found that a low platelet count, a high AST/ALT ratio, and the presence of Mallory bodies were significant predictors of severe liver fibrosis.

Entities:  

Year:  2002        PMID: 12479942     DOI: 10.1016/s1386-6346(02)00246-2

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  24 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

2.  Tumor necrosis factor-alpha, interleukin-1beta and nitric oxide: induction of liver megamitochondria in prehepatic portal hypertensive rats.

Authors:  Isabel Prieto; Fulgencio Jiménez; Maria-Angeles Aller; Maria-Paz Nava; Elena Vara; Cruz Garcia; Jaime Arias
Journal:  World J Surg       Date:  2005-07       Impact factor: 3.352

3.  Prolonged hepatitis caused by cytomegalovirus and non-alcoholic steatohepatitis in 16-year-old obese boy.

Authors:  Tatsuo Kanda; Osamu Yokosuka; Yutaka Suzuki
Journal:  Eur J Pediatr       Date:  2005-01-29       Impact factor: 3.183

Review 4.  Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis.

Authors:  Anisha A Gupte; Christopher J Lyon; Willa A Hsueh
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

5.  Influence of Roux-en-Y Gastric Bypass on the Hepatocellular Function and Bile Flow of Obese Patients Assessed by Scintigraphy with DISIDA.

Authors:  Wilson Salgado Júnior; Carlos Augusto de Mattos Donadelli; José Sebastião Dos Santos; Carla Barbosa Nonino
Journal:  Obes Surg       Date:  2016-11       Impact factor: 4.129

6.  Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease.

Authors:  Masaru Sakurai; Toshinari Takamura; Tsuguhito Ota; Hitoshi Ando; Hiroshi Akahori; Kyosuke Kaji; Motoko Sasaki; Yasuni Nakanuma; Katsuyuki Miura; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

7.  Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.

Authors:  Radan Bruha; Marie Jachymova; Jaromir Petrtyl; Karel Dvorak; Martin Lenicek; Petr Urbanek; Tomislav Svestka; Libor Vitek
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

8.  Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease.

Authors:  Katsutoshi Tokushige; Etsuko Hashimoto; Haruka Noto; Satoru Yatsuji; Makiko Taniai; Nobuyuki Torii; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-05-30       Impact factor: 7.527

9.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

10.  Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus.

Authors:  Layla Judi; Ala Toukan; Yousef Khader; Kamel Ajlouni; M Amer Khatib
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.